← Back to Search

Radiation Therapy

Radiation therapy for COVID-19 (VENTED Trial)

Phase 2
Recruiting
Led By Arnab Chakravarti
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Laboratory Diagnosis of COVID-19 based within 14 days of enrollment.
CT or radiographic findings typical of COVID-19 pneumonia within 5 days of enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 18 months post radiation delivery
Awards & highlights

VENTED Trial Summary

This trial is testing whether low doses of radiation can help to treat people with pneumonia caused by COVID-19.

Eligible Conditions
  • COVID-19
  • Coronavirus

VENTED Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

VENTED Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 18 months post radiation delivery
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 18 months post radiation delivery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mortality rate of subjects treated with whole lung low-dose radiation
Secondary outcome measures
Change in number of Intensive care unit days
Change in number of days using supplemental oxygen
Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated
+6 more

Side effects data

From 2013 Phase 3 trial • 397 Patients • NCT00004054
78%
Menopausal symptoms
60%
Urinary frequency
52%
Impotence
47%
Late RT Toxicity: Bladder: NOS
39%
Diarrhea NOS
27%
Late RT Toxicity: Bowel: NOS
26%
Fatigue
26%
Late RT Toxicity: Other GU: NOS
21%
Proctitis NOS
21%
Dysuria
14%
Libido decreased
14%
Dermatitis radiation NOS
12%
Late RT Toxicity: Other GI: NOS
12%
Late RT Toxicity: Other: NOS
12%
Hemoglobin decreased
12%
Alanine aminotransferase increased
9%
Gynaecomastia
8%
Urinary retention
7%
Pain-other
7%
Aspartate aminotransferase increased
6%
Rectal bleeding
6%
Constipation
6%
Leukopenia NOS
4%
Edema NOS
4%
Hematuria present
4%
Renal/GU-Other
3%
Arthralgia
3%
Blood creatinine increased
3%
Dyspnea NOS
3%
Dermatitis exfoliative NOS
2%
Nausea
2%
Hyperglycemia NOS
2%
Depression NEC
2%
Lymphopenia
2%
Myalgia
2%
Peripheral sensory neuropathy
1%
Stomatitis
1%
Blood albumin decreased
1%
Platelet count decreased
1%
Weight decreased
1%
Anorexia
1%
Hypocalcemia
1%
Hyponatremia
1%
Hematologic-Other
1%
Neutropenia
1%
Alopecia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Hormones and RT
Hormones and RT Plus Chemotherapy

VENTED Trial Design

1Treatment groups
Experimental Treatment
Group I: Radiation ArmExperimental Treatment1 Intervention
Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation therapy
2013
Completed Phase 3
~2850

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
319 Previous Clinical Trials
290,124 Total Patients Enrolled
1 Trials studying COVID-19
37 Patients Enrolled for COVID-19
Arnab ChakravartiPrincipal Investigator - James Cancer Hospital, Department of Radiation Oncology
Ohio State University Comprehensive Cancer Center
1 Previous Clinical Trials
158 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Mar 2025